Fulgent Genetics, Inc. (FLGT) key performance indicators and operating metrics (6 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Adjusted Earnings Before Interest, Taxes, Depreciation, and Amortization | 15.2M | FY2026-Q1 |
| Generally Accepted Accounting Principles Gross Margin | 30.20 percent | FY2026-Q1 |
| Non-Generally Accepted Accounting Principles Gross Margin | 32.30 percent | FY2026-Q1 |
| Non-Generally Accepted Accounting Principles Gross Profit | 23M | FY2026-Q1 |
| Non-Generally Accepted Accounting Principles Net Income | 5.2M | FY2025-Q4 |
| Core Business Revenue Excluding United States Centers for Disease Control and Prevention COVID Next-Generation Sequencing Testing | 81.7M | FY2025-Q2 |
Back to FLGT overview · FLGT earnings · FLGT holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.